Clinical trial
A Phase II Study of G3139 (Genasense ™) in Patients With Merkel Cell Carcinoma
NCT00079131 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of G3139 (Genasense ™) in Patients With Merkel Cell Carcinoma
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2004
- Completion date
- Not reported
- Enrollment
- 37 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent neuroendocrine carcinoma of the skin, stage i neuroendocrine carcinoma of the skin, stage ii neuroendocrine carcinoma of the skin, stage iii neuroendocrine carcinoma of the skin, stage iv neuroendocrine carcinoma of the skin